Kelix bio (Malta) Ltd.December 16, 2022

FDA 483 - Kelix bio (Malta) Ltd. - December 16, 2022

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Kelix bio (Malta) Ltd.

Record Details

Kelix bio (Malta) Ltd. received a Form 483 following an inspection that identified significant deficiencies in their drug manufacturing processes. Observations included a failure to thoroughly investigate batch discrepancies, inadequately designed equipment for sampling, and deficiencies in aseptic processing area cleaning. Additionally, the firm failed to document established test procedures at the time of performance.

Company: Kelix bio (Malta) Ltd.
Inspection Date: December 16, 2022
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
Person: William Leonard

Open in Dashboard

ID · 865dcc08-1f39-489b-95f0-66be1feb9d04